prevention and management of organ failures. Besides antimicrobial therapy and supportive care, no immunomodulatory strategy has yielded clear-cut and reproducible results in terms of improved survival [1] .
Polyvalent intravenous immunoglobulin (IVIG) preparations, that contain primarily IgGs, have long been used in various clinical situations. For example, IVIG has been shown to be efficacious when used as a replacement therapy in primary or secondary humoral immunodeficiencies or as an immunomodulatory therapy in a number of autoimmune and inflammatory diseases such as primary immune thrombocytopenia, Guillain-Barré syndrome, and Kawasaki's disease including severe clinical presentations with multiple organ dysfunction syndrome [2] . In addition, IVIG has also been used as an adjuvant treatment of sepsis given its potential effects both on pathogens and the host's response. How IVIG therapy may modulate the immune system in autoimmune diseases and in sepsis has been nicely reviewed elsewhere [3, 4] . Potential mechanisms of action of IVIG therapy in sepsis include (1) a role in pathogen recognition, clearance, and toxin scavenging; (2) modulation of pattern recognition receptors (inflammasomes), signalling pathways (NF-jB), and effector molecules (cytokines) of the immune response; and (3) a direct anti-apoptotic effect on immune cells.
IgM-enriched IVIG preparation exhibit additional immunomodulatory properties when compared with standard IVIG. Soluble IgM consists primarily of pentamers and are divided into natural and immune IgM. Natural IgM antibodies are constitutively secreted by B1 cells. Several elegant animal models have demonstrated the protective role of natural IgM against numerous viral, bacterial, and parasitic infections (Influenza, Pseudomonas aeruginosa, Plasmodium falciparum) and a worse outcome of patients with IgM deficiency [5] [6] [7] . IgM has an important role in the classical pathway of complement activation when complexed with antigens and its pentameric structure favors agglutination of the invading organism and its neutralization. IgM also favors interactions between pathogens and phagocytic cells, resulting in enhanced innate immune activation and improved antigen presentation. Recent reports have also identified a potential role of IgM in the maintenance of tissue homeostasis, through a C1q-mediated clearance of apoptotic and altered cells, and inhibition of inflammation (Fig. 1) [8, 9] .
Unfortunately the therapeutic potential of IVIG did not clearly translate into improved outcomes in septic patients. A number of prospective studies that addressed the efficacy of polyclonal IVIG in the treatment of septic shock have been included in several meta-analysis, including the recently updated one from the Cochrane Collaboration [10] . A primary analysis indicated a benefit of IVIG in survival that seemed even more pronounced when using IgM-enriched preparations. However, the interpretation of meta-analysis relies on several factors including an extensive assessment of the risk of bias, the respective weight related to the number of patients, as well as the marked influence of single-center studies on outcomes [11, 12] . Restriction to high-quality studies with a low risk of confounding factors did not show any benefit from IVIG administration with both standard and IgMenriched preparations [10] . Most importantly, the heterogeneous quality of IVIG preparations may represent a major but non-measurable bias across studies [13] . The main conclusion from the meta-analysis was that the current evidence for benefits was inconsistent and inconclusive, and indeed the latest version of the Surviving Sepsis Campaign guidelines in 2012 stated: ''we suggest not using intravenous immunoglobulins in adult patients with severe sepsis or septic shock (grade 2B)'' [14] .
An article recently published in Intensive Care Medicine is reviving the interest in IVIG for the treatment of septic shock. In a single-center retrospective study, Cavazzuti and colleagues [15] analyzed a cohort of septic shock patients who did (92 patients) or did not (76 patients) receive early treatment with polyclonal IgMenriched IVIG in addition to common 6-h and 24-h bundles. Routine administration of IgM-enriched IVIG preparations in septic patients was based on a published meta-analysis suggesting a survival benefit [10] . Administration of IgM was associated with a dramatic and impressive 21.1 % absolute improvement in 30-day survival (75 vs. 53.9 %) that persisted after appropriate adjustment through multivariate analysis as well as a propensity score-matching. Although the authors performed the most accurate and robust analysis of the retrospective data, their findings must be read with caution. The main limits of the study lie in its retrospective design and in the core question of the decision-making process of treatment allocation. Comparison between IVIG-treated and non-treated patients did not identify any significant baseline differences. However, some uncollected baseline characteristics, such as functional and nutritional status, as well as specific prognostic factors of underlying comorbidities may have influenced the decision whether or not to administer IVIG therapy. The study was not designed to address the mechanism of action of IgM-enriched preparations, but a decrease in the incidence of refractory shock and multiple organ failure in IgM-treated patients would grossly argue in favor of an anti-inflammatory role of IgM-enriched preparation. One can regret the lack of baseline measurement of total Ig levels as well as the distribution of Ig subsets prior to exogenous IVIG administration. Indeed, it has been reported that transient hypogammaglobulinemia may arise within the first days of septic shock and may be associated with increased mortality [16] .
Albeit interesting, the results of this retrospective single-center study are unlikely to challenge the results observed in prospective randomized clinical trials and to modify the current evidence against the use of IVIG in sepsis. But one must admit that the dramatic survival differences between treated and non-treated patients is intriguing enough to suggest a specific therapeutic effect of IgM-enriched IVIG preparations and to support further prospective interventional studies. Spin-off studies aimed at assessing the immune mechanisms whereby IgM-enriched IVIG preparations exert their effects would be welcome. This translational approach is essential for a careful evaluation of biological plausibility and mode of action of immunomodulatory therapies of sepsis, and may also help to identify which patients are likely to benefit from them.
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